Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $3.8 million.

  • Centessa Pharmaceuticals' Interest & Investment Income rose 12.72% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 72.50%. This contributed to the annual value of $14.0 million for FY2024, which is 33.79% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Interest & Investment Income stood at $3.8 million, which was down 14.04% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Interest & Investment Income registered a high of $7.9 million during Q1 2025, and its lowest value of $25,000 during Q2 2022.
  • Moreover, its 3-year median value for Interest & Investment Income was $3.2 million (2024), whereas its average is $3.7 million.
  • Data for Centessa Pharmaceuticals' Interest & Investment Income shows a peak YoY surged of 8,136.00% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Interest & Investment Income stood at $39,000 in 2022, then spiked by 7,420.51% to $2.9 million in 2023, then surged by 65.19% to $4.8 million in 2024, then climbed by 12.72% to $3.8 million in 2025.
  • Its Interest & Investment Income was $3.8 million in Q3 2025, compared to $4.4 million in Q2 2025 and $7.9 million in Q1 2025.